Study #SWOGS1216
SWOGS1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
TAK-700, Bicalutamide
Description
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Information and next steps
Disease:
Prostate Cancer
Study phase:
III
Physician name:
Paul Corn
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.